I was diagnosed in Dec. 24 with MDS following Myeloid NGS Pathology Report. This report identified I am positive for ASXL 1 & RUNx1 w/3 genetic variants. High risk per IPSS-M, WHO 5th Edition. I have had a 6 cycle Aranesp 500 mg a 2 wks. with insufficient response due to transfusion requirements. Currently receiving Vidaza 5of 6 cycles in with ongoing need for transfusions. Very concerned that current trt modalities are not sufficient & a likely transition to AML is in my future. That said, I’m interested in all the knowledge re: this potential phase of disease that I might face. Linda